First Time Loading...
K

Kaken Pharmaceutical Co Ltd
TSE:4521

Watchlist Manager
Kaken Pharmaceutical Co Ltd
TSE:4521
Watchlist
Price: 3 478 JPY 0.03% Market Closed
Updated: May 5, 2024

Kaken Pharmaceutical Co Ltd
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Kaken Pharmaceutical Co Ltd
Operating Income Peer Comparison

Comparables:
4502
4568
4578
4519
4503

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
K
Kaken Pharmaceutical Co Ltd
TSE:4521
Operating Income
¥4.5B
CAGR 3-Years
-38%
CAGR 5-Years
-28%
CAGR 10-Years
-11%
Takeda Pharmaceutical Co Ltd
TSE:4502
Operating Income
¥464.9B
CAGR 3-Years
7%
CAGR 5-Years
18%
CAGR 10-Years
17%
Daiichi Sankyo Co Ltd
TSE:4568
Operating Income
¥188B
CAGR 3-Years
37%
CAGR 5-Years
19%
CAGR 10-Years
5%
Otsuka Holdings Co Ltd
TSE:4578
Operating Income
¥294.7B
CAGR 3-Years
13%
CAGR 5-Years
32%
CAGR 10-Years
3%
Chugai Pharmaceutical Co Ltd
TSE:4519
Operating Income
¥444.2B
CAGR 3-Years
14%
CAGR 5-Years
29%
CAGR 10-Years
19%
Astellas Pharma Inc
TSE:4503
Operating Income
¥142B
CAGR 3-Years
-5%
CAGR 5-Years
-12%
CAGR 10-Years
3%

See Also

What is Kaken Pharmaceutical Co Ltd's Operating Income?
Operating Income
4.5B JPY

Based on the financial report for Dec 31, 2023, Kaken Pharmaceutical Co Ltd's Operating Income amounts to 4.5B JPY.

What is Kaken Pharmaceutical Co Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
-11%

Over the last year, the Operating Income growth was -71%. The average annual Operating Income growth rates for Kaken Pharmaceutical Co Ltd have been -38% over the past three years , -28% over the past five years , and -11% over the past ten years .